1. Home
  2. GHG vs CLLS Comparison

GHG vs CLLS Comparison

Compare GHG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GHG

GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

HOLD

Current Price

$1.72

Market Cap

205.1M

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.68

Market Cap

299.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHG
CLLS
Founded
2004
1999
Country
China
France
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.1M
299.0M
IPO Year
2018
2007

Fundamental Metrics

Financial Performance
Metric
GHG
CLLS
Price
$1.72
$4.68
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
17.2K
147.2K
Earning Date
12-26-2025
11-07-2025
Dividend Yield
5.81%
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$174,012,060.00
$82,551,000.00
Revenue This Year
$19.02
$32.58
Revenue Next Year
$8.26
N/A
P/E Ratio
$6.55
N/A
Revenue Growth
N/A
129.04
52 Week Low
$1.66
$1.10
52 Week High
$3.25
$5.48

Technical Indicators

Market Signals
Indicator
GHG
CLLS
Relative Strength Index (RSI) 29.21 53.17
Support Level $1.66 $4.47
Resistance Level $1.89 $5.45
Average True Range (ATR) 0.08 0.30
MACD -0.01 -0.03
Stochastic Oscillator 24.00 20.41

Price Performance

Historical Comparison
GHG
CLLS

About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: